Company: PRTA
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001559053-25-000044
Chunk: 10

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 10
---
 60.0

For prasinezumab, Roche is obligated to pay:

• up to $ 290.0

• up to $ 155.0

• up to $ 175.0

• tiered, high single-digit to high double-digit royalties in the teens based on U. S. and ex-U. S. annual net sales, subject to certain adjustments, with respect to the applicable Licensed Product.

Roche bore 100 In May 2021, the Company exercised its rights under the terms of License Agreement to receive potential U. S. commercial sales milestone and royalties, in lieu of a U. S. profit and loss share for prasinezumab in Parkinson’s disease. Thus, in the U. S., through May 28, 2021, the parties shared all development costs, all of which were allocated 70 30 70 30

The Company initiated a Phase 1 clinical trial for prasinezumab in 2014. Following the Phase 1 clinical trial, Roche became primarily responsible for developing, obtaining and maintaining regulatory approval for and commercializing Licensed Products. Roche also became responsible for the clinical and commercial manufacture and supply of Licensed Products.

In addition, the Company has an option under the License Agreement to co-promote prasinezumab in the U. S. in the Parkinson’s disease indication. If the Company exercises such option, it may also elect to co-promote additional Licensed Products in the U. S. approved for Parkinson’s disease. Outside the U. S., Roche will have responsibility for developing and commercializing the Licensed Products. Roche bears all costs that are specifically related to obtaining or maintaining regulatory approval outside the U. S. and will pay the Company a variable royalty based on annual net sales of the Licensed Products outside the U. S.

The License Agreement continues on a country-by-country basis until the expiration of all payment obligations under the License Agreement. The License Agreement may also be terminated (i) by Roche at will after the first anniversary of the effective date of the License Agreement, either in its entirety or on a Licensed Product-by-Licensed Product basis, upon 90 days’ prior written notice to the Company prior to first commercial sale and 180 days’ prior written notice to Prothena after first commercial sale, (ii) by either party, either in its entirety or on a Licensed Product-by-Licensed Product or region-by-region basis, upon written notice in connection with a material breach